|
1
|
Xu JX, Maher VE, Zhang L, Tang S, Sridhara
R, Ibrahim A, Kim G and Pazdur R: FDA approval summary: Nivolumab
in advanced renal cell carcinoma after anti-angiogenic therapy and
exploratory predictive biomarker analysis. Oncologist. 22:311–317.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gianchecchi E, Delfino DV and Fierabracci
A: Recent insights into the role of the PD-1/PD-L1 pathway in
immunological tolerance and autoimmunity. Autoimmun Rev.
12:1091–1100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Younes A, Santoro A, Shipp M, Zinzani PL,
Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V,
Kuruvilla J, et al: Nivolumab for classical Hodgkin's lymphoma
after failure of both autologous stem-cell transplantation and
brentuximab vedotin: A multicentre, multicohort, single-arm phase 2
trial. Lancet Oncol. 17:1283–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weber JS, Hodi FS, Wolchok JD, Topalian
SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et
al: Safety profile of nivolumab monotherapy: A pooled analysis of
patients with advanced melanoma. J Clin Oncol. 35:785–792. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Byun DJ, Wolchok JD, Rosenberg LM and
Girotra M: Cancer immunotherapy-immune checkpoint blockade and
associated endocrinopathies. Nat Rev Endocrinol. 13:195–207. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 26:2375–2391. 2015.PubMed/NCBI
|
|
15
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gettinger SN, Horn L, Gandhi L, Spigel DR,
Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman
DM, et al: Overall survival and long-term safety of nivolumab
(Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in
patients with previously treated advanced non-small-cell lung
cancer. J Clin Oncol. 33:2004–2012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blansfield JA, Beck KE, Tran K, Yang JC,
Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C,
et al: Cytotoxic T-lymphocyte-associated antigen-4 blockage can
induce autoimmune hypophysitis in patients with metastatic melanoma
and renal cancer. J Immunother. 28:593–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryder M, Callahan M, Postow MA, Wolchok J
and Fagin JA: Endocrine-related adverse events following ipilimumab
in patients with advanced melanoma: A comprehensive retrospective
review from a single institution. Endocr Relat Cancer. 21:371–381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishikawa M and Oashi K: Case of
hypophysitis caused by nivolumab. J Dermatol. 44:109–110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujimura T, Kambayashi Y, Furudate S,
Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R and Aiba S:
Isolated adrenocorticotropic hormone deficiency possibly caused by
nivolumab in a metastatic melanoma patient. J Dermatol. 44:e13–e14.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kitajima K, Ashida K, Wada N, Suetsugu R,
Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka
K, et al: Isolated ACTH deficiency probably induced by
autoimmune-related mechanism evoked with nivolumab. Jpn J Clin
Oncol. 47:463–466. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takaya K, Sonoda M, Fuchigami A and
Hiyoshi T: Isolated adrenocorticotropic hormone deficiency caused
by nivolumab in a patient with metastatic lung cancer. Intern Med.
56:2463–2469. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faje A: Immunotherapy and hypophysitis:
Clinical presentation, treatment, and biologic insights. Pituitary.
19:82–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Caturegli P, Di Dalmazi G, Lombardi M,
Grosso F, Larman HB, Larman T, Taverna G, Cosottini M and Lupi I:
Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein
4 blockade: Insights into pathogenesis from an autopsy series. Am J
Pathol. 186:3225–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Caturegli P, Newschaffer C, Olivi A,
Pomper MG, Burger PC and Rose NR: Autoimmune hypophysitis. Endocr
Rev. 26:599–614. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yanase T, Tajima T, Katabami T, Iwasaki Y,
Tanahashi Y, Sugawara A, Hasegawa T, Mune T, Oki Y, Nakagawa Y, et
al: Diagnosis and treatment of adrenal insufficiency including
adrenal crisis: A Japan Endocrine Society clinical practice
guideline [Opinion]. Endocr J. 63:765–784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Powles T, Albiges L, Staehler M, Bensalah
K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, et
al: Updated European association of urology guidelines
recommendations for the treatment of first-line metastatic clear
cell renal cancer. Eur Urol. Dec 7–2017;(Epub ahead of print).
|
|
31
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
